Abstract：
Lignan, a beneficial constituent of Flaxseed (Linum usitatissimum L.) showed great interest in researchers because of its multiple functional properties. Nonetheless, a challenge arises due to the glycosidic structure of lignans, which the gut epithelium cannot readily absorb. Therefore, we screened 18 strains of Lactiplantibacillus plantarum, Lacticaseibacillus casei, Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, Pediococcus pentosaceus, Pediococcus acidilactici, and Enterococcus durans to remove glycosides from flaxseed lignan extract enzymatically. Among our findings, Lactiplantibacillus plantarum SCB0151 showed the highest activity of β-glucosidase (8.91 ± 0.04 U/mL) and higher transformed efficiency of Secoisolariciresinol (SECO) (8.21 ± 0.13%). The conversion rate of Secoisolariciresinol diglucoside (SDG) and the generation rate of SECO was 58.30 ± 3.78% and 32.13 ± 2.78%, respectively, under the optimized conditions. According to the LC-HRMSMS analysis, SECO (68.55 ± 6.57 µM), Ferulic acid (FA) (32.12 ± 2.50 µM), and Coumaric acid (CA) (79.60 ± 6.21 µM) were identified in the biotransformation products (TP) of flaxseed lignan extract. Results revealed that the TP exhibited a more pronounced anti-inflammatory effect than the flaxseed lignan extract. SECO, FA, and CA demonstrated a more inhibitory effect on NO than that of SDG. The expression of iNOS and COX-2 was significantly suppressed by TP treatment in LPS-induced Raw264.7 cells. The secretion of IL-6, IL-2, and IL-1β decreased by 87.09 ± 0.99%, 45.40 ± 0.87%, and 53.18 ± 0.83%, respectively, at 60 µg/mL of TP treatment. Given these data, the bioavailability of flaxseed lignan extract and its anti-inflammatory effect were significantly enhanced by Lactiplantibacillus plantarum SCB0151, which provided a novel approach to commercializing flaxseed lignan extract for functional food.
摘要：
Lignan,亚麻籽的有益成分（LinumusitatissimumL.）由于其多种功能特性而对研究人员产生了极大的兴趣。尽管如此，由于木脂素的糖苷结构，肠上皮不易吸收。因此,我们筛选了18株植物乳杆菌，干酪乳杆菌，嗜酸乳杆菌，鼠李糖乳杆菌,戊糖片球菌,酸化小球菌，和durans肠球菌酶促去除亚麻籽木酚素提取物中的糖苷。在我们的发现中,植物乳杆菌SCB0151表现出最高的β-葡萄糖苷酶活性（8.91±0.04U/mL）和较高的Secoisolaricileresinol（SECO）转化效率（8.21±0.13％）。Secoisolariciresinol二葡萄糖苷（SDG）的转化率和SECO的生成率为58.30±3.78％和32.13±2.78％，分别,在优化条件下。根据LC-HRMSMS分析，SECO(68.55±6.57µM),阿魏酸(FA)(32.12±2.50µM),在亚麻籽木酚素提取物的生物转化产物（TP）中鉴定出香豆酸（CA）（79.60±6.21µM）。结果表明，TP比亚麻籽木酚素提取物表现出更明显的抗炎作用。SECO,FA,CA对NO的抑制作用优于SDG。TP显著抑制LPS诱导的Raw264.7细胞中iNOS和COX-2的表达。IL-6、IL-2、IL-1β的分泌减少87.09±0.99%,45.40±0.87%,和53.18±0.83%，分别,在60µg/mL的TP处理。鉴于这些数据,植物乳杆菌SCB0151显著提高了亚麻籽木酚素提取物的生物利用度和抗炎作用,为亚麻籽木酚素提取物的功能性食品商业化提供了新的途径。
